Key Metrics of Agenus
Revenue$156M▲ 59.5% YoYFY 2023
Operating income−$160M▲ 11.1% YoY
Net profit−$257M▼ 11.6% YoY
Shareholders' equity−$160M
Market cap$320MAGEN · $7.09
Competitors10identified
About Agenus
Sectors
Company details
- Website
- agenusbio.com
- Founded
- 2000
- Listed
- Nasdaq: AGEN (since 2000)
Operational Areas of Agenus
Pharmaceuticals & Healthcare›Biotechnology & Vaccines
Company summary
Legal nameAgenus Inc.
TickerAGEN
ExchangeNasdaq
CountryUnited States
SEC CIK0001098972
Listed since2000
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
SectorPharmaceuticals & Healthcare · Biotechnology & Vaccines
Websitehttp://www.agenusbio.com
US market & SEC filings
AGEN · Nasdaq · SEC CIK 0001098972
Last price · 30 Oct 2026
$7.09
−0.56%
Market cap$320M
P/E—On FY 2023 diluted EPS
Volume625,488
SectorHealth CareBiotechnology: Biological Products (No Diagnostic Substances)
Country · IPOUnited StatesListed 2000
AGEN share price
Premium
Annual results (SEC EDGAR)
Revenue, operating income, net income, EPS, cash flow, assets, liabilities, equity and debt for every year filed with the SEC are part of the premium plan.
Sign in to continue See plans & pricingVendor checks & payment capacity
Sign in with access to company financials to review vendor evidence.
Registered office and contact
Registered officeLexington
GSTIN—
Email—
Websitehttp://www.agenusbio.com
Members / shareholders—
Directors and key people
Directors are read from the MGT-7 annual return and AOC-4 signatories.
Competitors of Agenus
Competitors10identified
Countries1most in United States
Top competitors by location
| Company | Description | Domain | Founded | Location |
|---|---|---|---|---|
| Part of Vertex Pharmaceuticals. | vrtx.com | 1991 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | modernatx.com | 2018 | United States | |
 Becton Dickinson |
Biotechnology & Vaccines · Pharmaceuticals & Healthcare | bd.com | — | United States |
| Part of Illumina. | illumina.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | guardanthealth.com | 2018 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | revvity.com | — | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | exelixis.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | neurocrine.com | 1996 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | twistbioscience.com | 2018 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | biomarin.com | 1999 | United States |
Charges (secured borrowings)
0 registered charges. Lenders, amounts and dates are part of the premium plan.
Statutory auditors
Auditors are read from the AOC-4 auditor's report section.
Business activities and related parties
biotechnology
Filings
No filings on record yet.